Drugs / GCB-002
GCB-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06739434 | Nov 2024 → Dec 2026 expected | Rett syndrome | Genecombio Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GCB-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06739434 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “self-complementary AAV9 carrying a full length human MECP2 transgenetic product” NCT06739434 ↗ |
| Route | Intrathecal | “single intrathecal injection” NCT06739434 ↗ |
| Target | MECP2 | “full length human MECP2 transgenetic product” NCT06739434 ↗ |